Clinical Trials in Binzhou, China

7 recruiting

Showing 120 of 30 trials

Recruiting
Phase 2

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

HER2-negativeLow PD-L1 ExpressingUnresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University77 enrolled29 locationsNCT06932068
Recruiting
Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Ulcerative Colitis
Genentech, Inc.224 enrolled82 locationsNCT06979336
Recruiting
Phase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines150 enrolled64 locationsNCT06970743
Recruiting
Phase 3

Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

Severe Asthma
AstraZeneca400 enrolled76 locationsNCT07363642
Recruiting

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Chronic Obstructive Pulmonary Disease
AstraZeneca1,000 enrolled20 locationsNCT06862206
Recruiting
Phase 3

Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage

Intracerebral Hemorrhage
Beijing Tiantan Hospital1,192 enrolled41 locationsNCT07338175
Recruiting
Phase 2

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe
Eli Lilly and Company1,431 enrolled251 locationsNCT07415044
Recruiting
Phase 3

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Non-small Cell Lung Cancer
RemeGen Co., Ltd.574 enrolled66 locationsNCT07416474
Recruiting
Phase 1Phase 2

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

Ovarian CancerPancreatic CarcinomaAdvanced Solid Tumors+1 more
Evopoint Biosciences Inc.350 enrolled24 locationsNCT06799637
Recruiting
Phase 2

Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)

Ulcerative Colitis
InSilico Medicine Hong Kong Limited80 enrolled28 locationsNCT07265570
Recruiting
Phase 3

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Lupus Nephritis
Novartis Pharmaceuticals462 enrolled188 locationsNCT05126277
Recruiting
Phase 3

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

Lupus Nephritis
Novartis Pharmaceuticals315 enrolled25 locationsNCT06711887
Recruiting
Phase 1

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

MelanomaNon-small Cell Lung CancerRenal Cell Carcinoma
Shanghai Henlius Biotech174 enrolled69 locationsNCT07160335
Recruiting
Phase 3

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.560 enrolled68 locationsNCT07284134
Recruiting

To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice

Infertility
Ferring Pharmaceuticals2,500 enrolled28 locationsNCT07029451
Recruiting
Phase 3

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2

Acute Ischemic Stroke
Capital Medical University692 enrolled22 locationsNCT07263776
Recruiting
Phase 2

F573 for Injection for the Treatment of Liver Injury/Failure

Acute-On-Chronic Liver FailureAcute Liver Failure
Beijing Continent Pharmaceutical Co, Ltd.97 enrolled10 locationsNCT05689645
Recruiting
Phase 3

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 2

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Non-small Cell Lung Cancer
RemeGen Co., Ltd.80 enrolled34 locationsNCT06962865
Recruiting
Phase 3

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Breast Cancer (Early Breast Cancer)
AstraZeneca5,500 enrolled794 locationsNCT05952557